A month has gone by since the last earnings report for Revolution Medicines, Inc. (RVMD). Shares have lost about 8.8% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Revolution Medicines due for a breakout? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent drivers for Revolution Medicines, Inc. before we dive into how investors and analysts have reacted as of late.
Q4 Loss Wider Than Expected, Nil Sales
Revolution Medicines reported a fourth-quarter 2025 loss of $1.86 per share, wider than the Zacks Consensus Estimate of a loss of $1.56. The company had incurred a loss of $1.12 in the year-ago quarter.
Currently, the company does not have any approved products in its portfolio. It has yet to generate revenues.
Quarter in Detail
Research and development expenses amounted to $294.9 million, up nearly 57% year over year. This significant increase was primarily driven by higher costs associated with clinical studies and manufacturing for the company’s drug candidates.
General and administrative expenses amounted to $66.7 million, up more than 136% year over year. This upside was mainly due to increases in commercial preparation activities and employee-related expenses incurred during the quarter.
Full-Year 2025 Results
With no marketed products, Revolution Medicines did not record any revenues during the year.
The company posted a loss of $5.95 per share in 2025, wider than the $3.58 loss reported in the previous year.
2026 Guidance
The company issued fresh guidance for operating expenses. It expects the figure to be between $1.6 billion and $1.7 billion, which includes non-cash stock-based compensation expense of $180-$200 million.
How Have Estimates Been Moving Since Then?
Since the earnings release, investors have witnessed a downward trend in estimates review.
The consensus estimate has shifted -7.21% due to these changes.
VGM Scores
Currently, Revolution Medicines has a poor Growth Score of F, however its Momentum Score is doing a lot better with a C. However, the stock has a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Revolution Medicines has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Revolution Medicines is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Jazz Pharmaceuticals (JAZZ), a stock from the same industry, has gained 0.1%. The company reported its results for the quarter ended December 2025 more than a month ago.
Jazz reported revenues of $1.2 billion in the last reported quarter, representing a year-over-year change of +10.1%. EPS of $6.64 for the same period compares with $6.60 a year ago.
Jazz is expected to post earnings of $4.57 per share for the current quarter, representing a year-over-year change of +172%. Over the last 30 days, the Zacks Consensus Estimate has changed +28%.
Jazz has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of B.
Just Released: Zacks Top 10 Stocks for 2026
Hurry – you can still get in early on our 10 top tickers for 2026. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful.
From inception in 2012 through November, 2025, the Zacks Top 10 Stocks gained +2,530.8%, more than QUADRUPLING the S&P 500’s +570.3%.
Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2026. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Revolution Medicines, Inc. (RVMD): Free Stock Analysis Report
Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).